Results 1 to 10 of about 4,942 (259)

A Real-World Retrospective Analysis of Secondary Prevention Patients Treated with Inclisiran over 27 Months [PDF]

Clinical Medicine Insights: Cardiology
ASCVD is a global concern as it has become central to significant morbidity and mortality. LDL-C is the most important modifiable risk factor in developing ASCVD.
Carl Deaney, Meredith Donaldson, Agne Meskauskiene   +2 more
doaj   +4 more sources

Inclisiran: A New Pharmacological Approach for Hypercholesterolemia [PDF]

Reviews in Cardiovascular Medicine, 2022
Therapeutic approaches based on gene silencing technologies represent a new opportunity to manage hypercholesterolemia. Inclisiran is a small interfering RNA that targets proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA.
Stefania Angela Di Fusco, Aldo Pietro Maggioni, Chiara Bernelli, Francesco Perone, Vincenzo De Marzo, Edoardo Conte, Francesca Musella, Giuseppe Uccello, Leonardo De Luca, Domenico Gabrielli, Michele Massimo Gulizia, Fabrizio Oliva, Furio Colivicchi   +12 more
doaj   +4 more sources

Inclisiran in a real-world single-center registry of patients with very high atherosclerotic cardiovascular risk [PDF]

Atherosclerosis Plus
Background: A mean relative 50 % reduction of LDL cholesterol (LDLc) levels was observed in randomized studies in patients treated with inclisiran, a small-interfering-RNA therapeutic agent that reduces hepatic synthesis of PCSK9.
Antonio Centola, Michelangelo Carbonara, Serena De Nuzzo, Andrea Cuculo, Antonio Ruggiero, Giulio Campanale, Massimo Iacoviello, Paola Gargiulo, Pasquale Perrone Filardi, Natale Daniele Brunetti   +9 more
doaj   +3 more sources

Inclisiran for fast-track lipid-lowering treatment early after an acute coronary syndrome: a pilot study [PDF]

Atherosclerosis Plus
Background: Elevated low-density lipoprotein cholesterol (LDL-C) after acute coronary syndrome (ACS) significantly increases cardiovascular risk. Timely reduction of LDL-C is crucial, but it takes several weeks to achieve optimal LDL-C levels with ...
Alessandro Lupi, Martino Baluci, Simone Persampieri, Iacopo Perversi, Davide Presutti, Alberto Somaschini, Giovanni Vincenzo Gaudio, Luigina Guasti, Marc Ferrini, Alberto Corsini, Roberto De Ponti   +10 more
doaj   +3 more sources

Treatment With Inclisiran During Peritoneal Dialysis. [PDF]

JACC Case Rep
Background: Inclisiran is a small interfering RNA that prevents PCSK9 (proprotein convertase subtilisin/kexin type 9) synthesis, lowering low-density lipoprotein cholesterol. In ORION trials, efficacy and safety outcomes of inclisiran were similar among different renal impairment degrees, but no data are available in peritoneal dialysis (PD).
Sani E, Rinaldi E, Lupo MG, Orlandi E, Molinaroli E, Giachetti G, Ferri N, Zoppini G.   +7 more
europepmc   +7 more sources

The N‐Acetylgalactosamine‐conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low‐density lipoprotein cholesterol reductions [PDF]

Pharmacology Research & Perspectives, 2023
Inclisiran, a small interfering RNA, selectively inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) synthesis in the liver and has been shown to reduce low‐density lipoprotein cholesterol (LDL‐C) by ≥50% in patients with hypercholesterolemia ...
Dario Lehoux, David Kallend, Peter L. J. Wijngaard, Alan P. Brown, Brad Zerler   +4 more
doaj   +2 more sources

Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies [PDF]

American Heart Journal Plus, 2022
Study objective: This systematic review and meta-analysis aimed to assess the efficacy and safety profile of treatment with inclisiran, a drug that has been recently approved by the United States Food and Drug Administration (FDA) and the European ...
Arrigo F.G. Cicero, Federica Fogacci, Alberto Zambon, Peter P. Toth, Claudio Borghi   +4 more
doaj   +3 more sources

Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States [PDF]

JACC: Advances
Background: Many patients do not reach recommended low-density lipoprotein cholesterol (LDL-C) levels on statins alone. Inclisiran is a small interfering RNA providing ∼50% further reduction in LDL-C.
Nathan D. Wong, PhD, MPH, Hridhay Karthikeyan, MS, BS, Wenjun Fan, MD, PhD, MS, Batul Electricwala, PhD   +3 more
doaj   +2 more sources

EFFICACY AND SAFETY OF INCLISIRAN BY BASELINE BODY MASS INDEX: A POST HOC POOLED ANALYSIS OF THE ORION-9, ORION-10 AND ORION-11 PHASE III RANDOMIZED CONTROLLED TRIALS

American Journal of Preventive Cardiology, 2023
Therapeutic Area: ASCVD/CVD Risk Factors Background: Excessive bodyweight, often associated with dyslipidemia, may affect the pharmacology of drugs. Inclisiran, a small interfering RNA targeting PCSK9 hepatic mRNA, is an effective LDL-C lowering agent ...
Lawrence A Leiter, David G Kallend, Wolfgang Koenig, Ulf Landmesser, Kausik K Ray, Gregory G Schwartz, R Scott Wright, YannTong Chiang, Lorena Garcia Conde Orozco, Frederick J Raal   +9 more
doaj   +2 more sources

Inclisiran - hope in the fight against dyslipidemia [PDF]

Journal of Education, Health and Sport, 2023
Introduction:Lipid disorders are one of the most common modifiable risk factors for cardiovascular disease. Until now, the mainstay of dyslipidemia treatment was the use of widely available statins.
Paulina Krawiec, Karolina Madej, Izabela Wolanin, Bartłomiej Zielonka, Ilona Kowalczyk, Bartłomiej Stachyra, Marta Wolanin, Cezary Stawikowski, Barbara Dengler, Aleksandra Osińska   +9 more
doaj   +3 more sources